Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
85°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vbi Vaccines Inc CS
(NQ:
VBIV
)
0.5598
+0.0198 (+3.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vbi Vaccines Inc CS
< Previous
1
2
3
4
5
6
7
Next >
VBI Vaccines to Participate in Jefferies London Healthcare Conference
November 16, 2021
From
VBI Vaccines Inc.
Via
Business Wire
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 08, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
November 02, 2021
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...
Via
Benzinga
VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021
November 01, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open
October 13, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines to Participate in Upcoming Investor Conferences
October 04, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern
September 29, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 02, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Appoints Linda Bain to Board of Directors
July 07, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine
July 01, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Why Shares of VBI Vaccines Soared, and Then Fell 7%, on Tuesday
June 29, 2021
Investors almost seemed ready to take profits once shares hit their highest level since February.
Via
The Motley Fool
Exposures
COVID-19
VBI Vaccines Stock Is Trading Higher On Encouraging Data From COVID-19 Vaccine Candidate Trial
June 29, 2021
VBI Vaccines Inc (NASDAQ: VBIV) has announced positive Phase 1 data from its Phase 1/2 trial evaluating its enveloped virus-like particle (eVLP) COVID-19 vaccine...
Via
Benzinga
Exposures
COVID-19
VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19
June 29, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
June 23, 2021
From
Brii Biosciences
Via
Business Wire
VBI Vaccines to Present at Upcoming Scientific Conferences
June 17, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Results of Annual General Meeting
June 09, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021
June 09, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Why Agenus Stock Is Jumping Today
June 08, 2021
There was some positive news, but it probably wasn't a huge catalyst for the stock.
Via
The Motley Fool
Exposures
Product Safety
VBI Vaccines' Brain Cancer Immunotherapy Gets FDA Fast Track Review; Announces Updated Tumor Response, Overall Survival Data
June 08, 2021
The FDA has granted Fast Track Designation for VBI Vaccines Inc's (NASDAQ: VBIV) VBI-1901, its cancer vaccine immunotherapeutic candidate to treat...
Via
Benzinga
Exposures
Product Safety
VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM
June 08, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines to Participate in Upcoming Investor Conferences
June 01, 2021
From
VBI Vaccines Inc.
Via
Business Wire
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...
Via
Benzinga
Exposures
Product Safety
4 Biotech Stocks Wall Street Analysts Predict Will Gain More Than 60%
May 22, 2021
The integration of technology and successful clinical trials for treating critical ailments have boosted Wall Street’s optimism about several biotech stocks. Analysts expect Bionano, Cerus, Agenus and...
Via
Talk Markets
VBI Vaccines Secures $12M In Second Tranche of Debt Financing With K2 HealthVentures
May 21, 2021
VBI Vaccines Inc (NASDAQ: VBIV) has announced an agreement to draw down a $12 million second tranche under its previously announced debt financing facility with K2...
Via
Benzinga
VBI Vaccines Announces $12 Million Second Tranche of Debt Financing with K2 HealthVentures
May 21, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines to Present Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
May 20, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines' Three-Antigen HBV Vaccine Candidate Trial Data Published In Lancet Infectious Diseases
May 12, 2021
VBI Vaccines Inc (NASDAQ: VBIV) has announced that results from Phase 3 PROTECT trial of VBI's prophylactic 3-antigen hepatitis B (HBV) vaccine candidate...
Via
Benzinga
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases
May 12, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 10, 2021
From
VBI Vaccines Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.